Clinical Trial Update: Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravitreal KIO-104 for macular edema. The study is currently recruiting to assess safety, tolerability and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema

Drugs mentioned

• KIO-104

Snippet

Sponsor: Kiora Pharmaceuticals, Inc. | Conditions: Macular Edema | Phase 2 | Status: RECRUITING